Summary: Research is shifting attention from weight loss to addiction treatment: a new animal study finds that tirzepatide—the active ingredient in Mounjaro—substantially reduces alcohol intake and suppresses relapse-like drinking behavior.
In rodent models, voluntary alcohol consumption fell by more than half and binge-like drinking episodes were markedly reduced. The investigators report that tirzepatide dampens the brain’s reward response to alcohol, notably by reducing dopamine signaling in the lateral septum, a region implicated in motivation and addictive behaviors.
Key Facts
- 50% Reduction: Animals receiving tirzepatide consumed less than half the alcohol consumed by control animals.
- Relapse Prevention: After forced abstinence, treated animals did not show the typical rebound increase in drinking; intake remained low.
- Dopamine Blunting: Tirzepatide reduced alcohol-induced dopamine surges in reward circuitry, particularly within the lateral septum.
- Dual Action: Unlike drugs that act only on GLP-1 receptors, tirzepatide is a dual agonist of GIP and GLP-1 receptors, which may provide broader modulation of reward-related pathways.
- Epigenetic Signals: The study found alterations in histone-associated proteins in the lateral septum, suggesting potential long-term shifts in gene regulation linked to reward processing.
Source: University of Gothenburg
Background and context
Previous work from the University of Gothenburg showed that semaglutide—the GLP-1 receptor agonist found in weight-loss medications such as Ozempic and Wegovy—can lower alcohol consumption in rodents. The current study, published in eBioMedicine, extends that line of investigation to tirzepatide, a dual GIP/GLP-1 receptor agonist marketed as Mounjaro for type 2 diabetes and weight management.
In experimental paradigms that measure voluntary intake, binge-like consumption and relapse-like behavior, tirzepatide consistently reduced alcohol-seeking and drinking across both male and female animals. The reduction in alcohol intake was robust and sustained during repeated dosing.
“We saw clear, long-lasting reductions in alcohol consumption, binge-like drinking and relapse-like drinking in both sexes. Importantly, our data also reveal mechanistic changes in brain reward circuits that could explain these behavioral effects,” says Christian Edvardsson, doctoral student in pharmacology at the Sahlgrenska Academy, University of Gothenburg.
Blunting alcohol’s rewarding effects
Tirzepatide is the first approved medication to act as a dual agonist at receptors for the satiety hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Its clinical safety profile is well established for diabetes and obesity, which may accelerate translational research into alcohol use disorder (AUD).
The researchers found that tirzepatide reduced alcohol-driven increases in dopamine, a neurotransmitter central to reward and reinforcement. Microdialysis and related measures indicate that the lateral septum, a brain region linked to motivation, reward and relapse vulnerability, is a key locus of these effects. Electrophysiological data also showed sustained synaptic depression in this area after treatment.
In addition to changes in neurotransmitter dynamics, proteomic analysis revealed modulation of histone-associated proteins in the lateral septum—molecules that influence gene expression. While these epigenetic-like changes do not by themselves prove causation, they point to potential durable molecular adaptations triggered by tirzepatide that could underlie reduced alcohol seeking.
Implications for future treatments
The study was a collaborative effort between the University of Gothenburg and the Medical University of South Carolina, integrating behavioral assays (locomotor activity, conditioned place preference), alcohol intake models (intermittent access two-bottle choice, drinking in the dark, alcohol deprivation effect), neurochemical measurements and molecular profiling.
“This is not yet a new clinical treatment for alcohol use disorder. Nonetheless, the findings strengthen the idea that drugs targeting gut–brain peptides and their receptors could be promising candidates for AUD treatment,” says Elisabet Jerlhag Holm, Professor of Pharmacology at the Sahlgrenska Academy.
Key Questions Answered:
A: The animal results are promising but not definitive. Robust effects in rodents support further research, yet human clinical trials are required to determine safety and efficacy for alcohol use disorder. Because tirzepatide is already approved for diabetes and obesity, its known safety profile may speed future clinical testing.
A: Appetite and addiction share overlapping reward circuits in the brain. Drugs that modulate gut–brain hormones such as GLP-1 and GIP appear to reduce reward-driven behaviors, which can diminish both food craving and alcohol consumption by attenuating dopamine-driven reinforcement.
A: The data suggest it does not alter taste per se. Instead, tirzepatide reduces the brain’s motivational response to alcohol, blunting the reinforcing “buzz” and suppressing relapse-like urges after sobriety.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The full journal paper was reviewed for this summary.
- Additional context and explanation were provided by the editorial staff.
About this neuropharmacology and AUD research news
Author: Peter Larsson
Source: University of Gothenburg
Contact: Peter Larsson – University of Gothenburg
Image: Image credited to Neuroscience News
Original Research: Open access. “Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents” by Christian E. Edvardsson et al., published in eBioMedicine. DOI: 10.1016/j.ebiom.2025.106119
Abstract
Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents
Background
Alcohol use disorder remains a major public health concern with limited pharmacological options. Peptides of the gut–brain axis influence mesolimbic reward circuitry and are emerging as promising targets for AUD intervention.
Methods
The researchers evaluated tirzepatide, a long-acting GIPR/GLP-1R agonist, using behavioral assays (locomotor activity, conditioned place preference), alcohol intake paradigms (intermittent access two-bottle choice, drinking in the dark, alcohol deprivation effect), and molecular analyses including microdialysis, electrophysiology and proteomics in rodent models.
Findings
Tirzepatide reduced alcohol’s rewarding properties—diminishing locomotor stimulation, conditioned place preference and nucleus accumbens dopamine release—and dose-dependently lowered voluntary alcohol consumption. It prevented binge-like and relapse-like drinking and retained efficacy with repeated administration. The drug induced sustained synaptic depression and altered histone-regulatory proteins in the lateral septum, and it affected metabolic measures such as body weight, adipose tissue mass and hepatic triglycerides, as well as circulating inflammatory markers.
Interpretation
Collectively, these results indicate that tirzepatide modulates alcohol-related behaviors through reward-related neural mechanisms and influences physiological consequences linked to chronic alcohol use. Given its established clinical use for metabolic disorders and consistent preclinical effects, tirzepatide warrants further investigation as a potential treatment for alcohol use disorder and its complications.